EDAP TMS SA annual report, Q4 FY2020

EDAP TMS S.A. — FY 2020 Form 20-F

Reporting period: Year ended December 31, 2020; filed April 7, 2021. This is an annual report, not a standalone fourth-quarter filing. Financial statements are prepared under U.S. GAAP and reported in euros.

Business context and results

EDAP develops and sells minimally invasive medical devices, including robotic high-intensity focused ultrasound (HIFU) systems for prostate cancer, extracorporeal shockwave lithotripsy (ESWL) devices, and complementary third-party products through its Distribution division. The company reorganized its reporting into these three divisions in 2020.

Metric (€ millions, except per-share data)FY 2020FY 2019Change
Total revenue41.744.9-7.2%
Gross profit18.421.0-12.5%
Gross margin44.1%46.8%-2.7 percentage points
Operating income0.32.2Lower
Net income (loss)(1.7)1.5Turned to loss
Basic and diluted EPS(€0.06)€0.05Turned to loss
Operating cash flow2.03.8Lower
Cash and cash equivalents, year-end24.720.9Higher

Revenue by division was HIFU €11.4 million (down 19.1%), ESWL €12.9 million (down 9.2%), and Distribution €17.3 million (up 4.6%). HIFU and ESWL sales were affected by COVID-related treatment cancellations and delayed hospital equipment purchases; Distribution growth reflected Exact Imaging sales and higher recurring service-related revenue.

Cash, debt and liquidity

  • Cash increased by €3.8 million to €24.7 million. Net cash from operating activities was €2.0 million; investing activities used €2.0 million; financing activities provided €3.2 million. Financing cash flow included new long-term borrowings of €4.8 million, principally COVID-related assistance loans.
  • At year-end, short-term borrowings were €2.6 million and long-term debt was €5.7 million, of which €4.5 million was current. Finance lease obligations totaled €0.9 million. Operating lease obligations were €1.9 million.
  • Current assets were €45.4 million and current liabilities €21.5 million. Management said working capital was sufficient for current requirements, while noting that demand and cash flows can fluctuate.
  • No dividends were paid for 2020; management did not anticipate a dividend, subject to shareholder approval.

Material changes, outlook and risks

  • COVID-19: The pandemic disrupted procedures, device sales and installations. Management expected near-term cancellations and purchasing delays to continue, with timing and financial impact uncertain.
  • Strategy and investment: EDAP refocused development on HIFU and discontinued ESWL R&D, including the Endo-Up platform; a €0.5 million inventory/prototype allowance related to that discontinuation was recorded. The company stopped manufacturing the Sonolith i-sys in 2020 but intends to maintain its existing ESWL business.
  • HIFU commercialization: U.S. Category 1 CPT reimbursement became effective January 1, 2021. CMS payment rules established an approximate national average of $4,400 for hospitals and $997 for physicians per Medicare procedure in a facility setting. Broader private-insurer coverage and adoption remain uncertain.
  • Management outlook: EDAP expected R&D spending to rise to about 11.5% of revenue from 2021 and anticipated higher sales and marketing expenses as it accelerates U.S. HIFU adoption. It provided no specific revenue or profit forecast.
  • Development and regulation: HIFU studies and new indications require successful clinical results and regulatory approvals. EU Medical Device Regulation requirements were due to apply from May 2021; Japanese approval for Focal One would require a clinical trial. The company halted the planned per-operative liver cancer Phase II study and is considering other liver and pancreatic applications.
  • Other exposures: Risks include dependence on one French manufacturing site and some single-source suppliers, competition and reimbursement uncertainty, foreign-exchange movements, and distributor relationships. The company reported a €1.4 million net foreign-exchange loss in 2020 and two payments associated with fraudulent supplier invoices; it recorded a €0.1 million contingency related to bank fraud.
  • Controls and audit: Management and KPMG reported effective internal control over financial reporting at year-end; a previously reported material weakness was deemed remediated. KPMG issued unqualified opinions on the financial statements and internal controls.

Important facts for investors to verify

  • Whether the 2021 CPT reimbursement rates translate into increased U.S. procedures, device sales and broader payer coverage.
  • Whether COVID-related delays and cancellations ease, and how hospital purchasing and treatment volumes affect revenue and operating cash flow.
  • The repayment or extension terms of COVID assistance loans, particularly the €4.0 million French government-guaranteed loans initially due in 2021.
  • Progress, enrollment and results for HIFU clinical studies, as well as MDR compliance and Japanese regulatory plans.
  • The margin and growth contributions of HIFU versus ESWL and Distribution; the filing’s narrative and segment tables contain some differing prior-year ESWL revenue figures.
  • Potential cash, control or reputational consequences from fraudulent invoice payments and the status of related recovery or mitigation efforts.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.